• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Morgan Stanley Ins Muni Secs

Morgan Stanley Ins Muni Secs

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Media Alert: Cadence to Showcase Latest RF Solutions at International Microwave Symposium 2015

    Media Alert: Cadence to Showcase Latest RF Solutions at International Microwave Symposium 2015

  2. RADCOM Reports Strong Results For Q1 2015: 16% Revenue Growth, Record 82% Gross Margin, $1.3M Operating Profit, $0.10 EPS (Non-GAAP)

    RADCOM Reports Strong Results For Q1 2015: 16% Revenue Growth, Record 82% Gross Margin, $1.3M Operating Profit, $0.10 EPS (Non-GAAP)

  3. Versar, Inc. Awarded $11 Million Contract To Continue Work At Joint Base Lewis-McChord

    Versar, Inc. Awarded $11 Million Contract To Continue Work At Joint Base Lewis-McChord

  4. TSP (Technology Service Professionals) Acquires Service Contract Portion of IMS

    TSP (Technology Service Professionals) Acquires Service Contract Portion of IMS

  5. Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation

    Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation

  6. Meet Pharma's Newest Movers and Shakers, Driving M&A

    Meet Pharma's Newest Movers and Shakers, Driving M&A

  7. Meet Pharma's Newest Movers and Shakers, Driving M&A

    Meet Pharma's Newest Movers and Shakers, Driving M&A

  8. Solera Holdings, Inc. to Enhance Engagement among Vehicle Owners, Manufacturers, Dealers and Service Providers by Acquiring DMEautomotive, LLC

    Solera Holdings, Inc. to Enhance Engagement among Vehicle Owners, Manufacturers, Dealers and Service Providers by Acquiring DMEautomotive, LLC

  9. Versar, Inc. Awarded General Services Adminstration Contract Valued At $4.5 Million

    Versar, Inc. Awarded General Services Adminstration Contract Valued At $4.5 Million

  10. IMBRUVICA® (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL)

    IMBRUVICA® (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL)

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.